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Abstract
Background: Immunoglobulin D multiple myeloma (MM) is rare and has a poorer prognosis than other MM
isotypes.
Design and methods: Seventeen patients (pts) diagnosed from 1993 to 2009 with IgD MM were selected from six
institutions of Multiple Myeloma Latium-Region GIMEMA Working Group.
Results: Median age was 55 years, 14 patients had bone lesions, eight had renal impairment with estimated
glomerular filtration rate (eGFR) < 50 ml/min, one serum calcium ≥ 12 mg/dl, 11 had lambda light chains, five
stage III of ISS, six with chromosomal abnormalities. Six pts received conventional chemotherapy (CT): five
melphalan + steroids based regimens. Eleven underwent high-doses of chemotherapy with autologous stem cell
transplantation (HDT/ASCT), five single and six tandem ASCT: six received bortezomib and/or thalidomide as
induction therapy and five VAD. Thalidomide maintenance was used in two pts: one in HDT/ASCT and one in CT
group; bortezomib was used in one patient after HDT/ASCT. At a median follow up of 38 (range 19-60) and 50
months (range 17-148) for pts treated with CT and HDT/ASCT, respectively, the overall response rate (ORR) was
83% and 90%. In the group of patients treated with CT, median overall survival (OS) was 34 months (95% CI 15- 54
months), median progression free survival (PFS) was 18 months (95% CI 3-33 months) and median duration of
response (DOR) was 7 months (95% CI 5-9 months). Median OS, PFS and DOR were not reached at the time of this
analysis in the HDT/ASCT group of patients. Death was observed in 27.3% of pts treated with HDT/ASCT and in
66.7% undergone CT.
Conclusions: Despite the retrospective analysis and the small number of pts our study showed that the use of
HDT/ASCT seems to improve also the prognosis of IgD MM patients. Treatment options including new drugs,
before and after stem cell transplantation, may further improve the outcomes of these patients.
Background
Immunoglobulin (Ig)D multiple myeloma (IgD MM) is a
rare subtype of myeloma, accounts for less than 2% of
all myelomas [1] and is accompanied with aggressive
course, resistance to chemotherapy and poor outcome.
It is often associated with relatively high frequencies of
renal failure, extra osseous disease, hypercalcemia, amy-
loidosis and Bence-Jones proteinuria [2-5]. The survival
of patients with IgD MM has been reported to be
shorter than that of patients with other types of M-pro-
tein [2,4,6]. However, there are reports of long survival
in patients with IgD MM treated with alkylating drugs
[7-9], interferon-alfa monotherapy [10] or autologous
stem cell transplantation (ASCT) [11-15]. Over the past
10 years, there has been substantial progress in the
treatment of MM, prospective randomized trials have
shown the superiority of high-doses of chemotherapy
with autologous stem cell transplantation (HDT/ASCT)
over standard therapy (CT) and new drugs, such as
immunomodulatory agents and proteasome inhibitors,
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ments may have led to changes in the outcomes of IgD
MM.
In this report we present the results of a retrospective
analysis of 17 cases with IgD MM treated with CT or
HDT/ASCT in six institutions of Multiple myeloma
Latium-Region GIMEMA Working Group between 1993
and 2009.
Design and methods
A retrospective analysis was carried out of 17 patients
with IgD MM diagnosed from 1993 to 2009 in six insti-
tutions from Multiple Myeloma Latium-Region
GIMEMA Working Group. Patients who had overt MM
based on International Myeloma Working Group
(IMWG) diagnostic criteria were selected.
Definition of response
Disease response was assessed using the IMWG criteria
[16,17]. Briefly, a partial response (PR) was defined as a
50% or higher decrease in the serum monoclonal pro-
tein (M-protein) levels from baseline and a reduction
90% or greater in 24 hour urine M-protein excretion or
less than 200 mg/24 hours; a very good partial respone
(VGPR) required a 90% or greater reduction in serum
M-protein and urinary M-protein less than 100 mg/24
hours or M-protein detectable by immunofixation but
not by electrophoresis. A complete response (CR) was
defined as negative serum and urine immunofixation
and less than 5% plasma cells on bone marrow examina-
tion. Disease that did not satisfy the criteria for PR,
VGPR, CR or progressive disease was classified as stable
disease (SD). Disease progression required any of the
following: 25% or greater increase from lowest response
value in serum M-protein (absolute ≥ 0.5 gr/dl) or urine
M-protein (absolute ≥ 200 mg/24 hours).
Progression free survival (PFS) was calculated from
start of first treatment to disease progression or death
from any cause, or the date the patient was last known
to be in remission. Overall survival (OS) was calculated
from start of first treatment to the date of death or the
date the patient was last known to be alive. Duration of
response (DOR) was calculated from the time of first
response achievement, that is at least PR, to the time of
disease progression, with deaths owing to causes other
than progression not counted, but censored.
For the analysis of treatment responses, PFS and OS,
the patients were divided into two groups: one group
was treated with HDT/ASCT, the other group received
treatment with conventional-dose chemotherapy.
Statistical analysis
Data cut-off was April 2011; patient characteristics were
summarized using descriptive statistics such as median
and range for quantitative variables and frequencies for
qualitative.
Progression free survival, overall survival and duration
of response were estimated according to the Kaplan-
Meier method. We used the Cox proportional hazards
regression model to estimate hazard ratios and 95% CIs.
Differences between survival curves were tested for sta-
tistical significance with the two-sided log-rank test.
Patients
A total of 17 patients with IgD MM was identified,
patients characteristics are listed in Table 1. The median
age of the patients was 55-years (range 37-78); 8/17
patients had ECOG performance scores > 2 and 14 had
≥ 1 lytic bone lesions. Eight patients (47%) had renal
Table 1 Patient characteristics at diagnosis
Number of patients = 17
Male/Female 11/6
Median Age at diagnosis yr (range) 55 (37-78) years
≤ 65 y = 13 (76.5%), ≥ 65 y = 4
(23.5%)
ISS stage at diagnosis
I7
II 2
III 5
Unknown 3
Performance status
ECOG < 2 9
ECOG > 2 8
Light chain type
k6
l 11
Bone marrow infiltration 30% (10-70%)
Extra osseous disease 0
Bone lesions 14/17 (82%)
Median serum monoclonal protein
g/dl
1.05 (0.09-5)
Median Urine monoclonal protein
g/24 h
0.79 (0-28)
Urine immunofixation positive 12/17 (70%)
Serum b2 microglobulin > 5.5 mg/
L
5/17 (29%)
Serum albumin < 3.5 g/dl 5/17 (29%)
eGFR < 50 ml/min 8/17 (47%)
Serum Calcium > 12 mg/dl 1/17
Amyloidosis 1/17
Hemoglobin g/dl, median (range) 11.9 (6.5-15)
< 10 5/17 (29%)
WBC count 10
9/L, median (range) 6.57 (3.19-16.8)
>7×1 0
9/L 7/17 (41%)
Platelet count 10
9/L, median
(range)
214 (74-518)
< 100 × 10
9/L 1/17
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(eGFR) < 50 ml/min, one patient had hypercalcemia
(serum calcium concentration ≥ 12 mg/dl), 11 patients
had lambda light chains (64%) and Bence-Jones protei-
nuria in 70%. Five patients were of stage III according
to ISS; cytogenetic analysis by fluorescence in situ hybri-
dization (FISH) was possible in six of eleven patients
and the abnormalities are shown in Table 2. Only one
patient was positive for amyloidosis at baseline.
Results
Six patients were treated with CT, five with Melphalan
plus steroids based regimens and one with VAD (Vin-
cristine, Adriamycin and Dexametasone) plus CED
(Cyclophosphamide, Etoposide, Dexamethasone); one
patient showed a CR, two VGPR, two PR and one SD.
Thalidomide was used as maintenance in the patient
who obtained CR after CT. The overall response rate
(ORR) was 83%; after a median follow up of 38 months
(range 19-60) for patient treated with conventional che-
motherapy, the median OS was 34 months (95% CI 15-
54 months) and the median PFS was 18 months (95%
CI 3-33 months). Median DOR was 7 months (95% CI
5-9 months).
Eleven patients underwent HDT/ASCT, as part of
their front line therapy, five patients received single and
six tandem ASCT. Six out of 11 patients received induc-
tion chemotherapy including thalidomide and/or borte-
zomib and five VAD. After ASCT single or tandem, five
patients obtained CR, three VGPR, two PR and one SD.
One patient in PR after HDT/ASCT received mainte-
nance with bortezomib and another patient also in PR
received Thalidomide as maintenance treatment both
patients maintained PR. The ORR in patients treated
with HDT/ASCT was 90% after a median follow up of
50 months (range 17-148); median OS, PFS [Figures 1,
2] and DOR are not reached. The log-rank test for DOR
was P = 0.23.
A progression or relapse was observed in 4/11 (36.4%)
patients treated with HDT/ASCT and in 4/6 (66.7%) of
those undergone CT. The log-rank test for PFS was P =
0.10, the hazard ratio was 0.31 (95% CI 0.07-1.40). One
patient who received single ASCT was treated with allo-
geneic transplantation at relapse. Peripheral neurophaty
of grade 1-2 was observed in all patients treated with
thalidomide and or bortezomib either in induction or in
maintenance therapy. All patients with bone disease
received bisphosphonates; patients treated with thalido-
mide, received aspirin or low molecular-weight heparin
as thromboprophylaxis and nobody developed venous
thromboembolism.
Seven of 17 patients had died by the time of analysis:
four in the group treated with CT and three in the
group of HDT/ASCT, 85% of death for disease progres-
sion; there were no peritransplant deaths. Comparing
OS with log-rank test we obtained P = 0.18, the hazard
ratio was 0.37 (95% CI 0.08-1.68). FISH analysis was
available only for 6/17 of cases, in these six patients
Table 2 Interphase FISH cytogenetic profile results
Number of patients = 17
Not available 11
Available 6
del(13q) 1/6
del(6q) 1/6
t(11;14) 2/6
-Y 1/6
+11 1/6
Figure 1 Overall Survival of HDT/ASCT and CT groups.
Figure 2 Progression free survival of HDT/ASCT and CT groups.
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OS, PFS or DOR
Discussion
The clinical features of our patients reported in this
study underline the worse characteristics of IgD MM.
As in other series described in the literature [18], we
also found an advanced stage and a younger age at pre-
sentation, with more aggressive clinical course. In addi-
tion, the poor survival of the patients may be associated
with problems related to delayed diagnosis [13,19].
Patients with renal failure of unknown cause, bone
pain, small serum M-protein bands, or unidentified Ig
isotype should be suspected for IgD MM. However, the
underlying tumor biology responsible for the differences
between IgD MM and other MM isotypes remains to be
defined.
IgD MM should be considered a rare subgroup of
MM with aggressive features rather than a single para-
meter of poor prognosis.
Jancelewicz et al. [2] reported that l light-chains are
f o u n di n9 0 %a n da l m o s tt h et o t a l i t yo fp a t i e n t sh a d
Bence-Jones proteinuria. A mean survival of 13.7 months
from diagnosis, that was worse than the common myelo-
mas, was observed in this study. Bladé et al [4] reviews
outcomes in 53 patients from 1965 to 1992 and observed
l light-chain disease in 60%, Bence Jones proteinuria in
96%, renal failure in 33% and hypercalcemia in 22%. Shi-
mamoto et al [6] reviewed 165 cases with IgD MM and
on multivariate analysis showed that l light-chains and
white blood cell count > 7 × 10
9 where adverse prognos-
tic markers. In our series we registered in 11 out of 17
patients (64%) the presence of l light-chains and Bence-
Jones proteinuria in 70%, renal impairment with eGFR <
50 ml/min in 8 cases (47%), extra osseous disease was
not seen in our patients at diagnosis. Many studies have
shown a poorer prognosis of IgD myeloma than other
MM isotypes. Bladé et al. [4] observed an overall
response to therapy of 58% with a median overall survival
of 21 months and 5-years survival was 21%. However,
these results were obtained before the use high-dose
therapy. Wechalekar et al in 11 cases IgD myeloma trea-
ted with autologous stem cell transplantation reported
18% CR and 82% PR, compared with a group of 14
patients who received conventional chemotherapy alone
in which was observed 0% CR and 43% PR. Maisnar et al
[13] reviewed 26 cases with IgD MM; ten were treated
with first-line high-dose chemotherapy using melphalan
200 mg/m
2 followed by ASCT and 70% achieved a CR
and 100% had at least a PR. The median PFS was18
months for patients who received ASCT and 20 months
for those who received conventional chemotherapy.
However, the median OS for ASCT group had not been
reached, in contrast the median OS for chemotherapy
group was only 16 months, which was statistically signifi-
cant (P = 0.005). More recently Kim et al [17] retrospec-
tively reviewed 75 patients with IgD myeloma from the
Korean Myeloma Registry data base; among 34 patients
(45%) treated with ASCT who were in CR or PR, after
induction therapy, had a median OS of 30 months (95%
CI 17.7-42.3 months) significantly longer than that of
patients treated with conventional chemotherapy (16.4
months, P = 0.012).
Conclusions
The small group of patients suffering from IgD multiple
m y e l o m ai sr a r ea n dc o n s i d e r e dt oh a v eap o o rp r o g -
nosis compared to other MM isotypes. Our report,
based on analysis of a cohort of 17 patients treated over
two decades in six institutions, shows that the use of
HDT/ASCT increased OS and PFS by 63% and 69%,
respectively, in comparison with those of patients trea-
ted with conventional chemotherapy. Thus, the advan-
tage of HDT/ASCT over conventional chemotherapy
seems confirmed, although the small number of patients
limited the statistical power of the analysis.
New drugs, such bortezomib, thalidomide, lenalido-
mide used as induction and consolidation in the stem
cell transplantation program, may well improve the out-
comes of IgDMM.
The clinical features and prognosis of patients with
IgDMM differ from those that characterize patients with
other immunoglobulin MM subtypes. The underlying
tumor biology responsible for these differences remains
to be determined. New treatment strategies that aim to
induce high-quality responses before ASCT and main-
tain the response after ASCT may be needed to improve
the outcomes of such patients.
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